Amarantus Bioscience Holdings Inc (AMBS)

[Sccrbrg]

It's just too expensive, and with Lympro projections falling - shareholders will have to foot them bill. In totality this is going to cost well over 20 million dollars and probably amp up their cash burn rate.

Means more crappy financing deals and dilution to look forward too. Almost every holding AMBS has is 3-4+ years out.

Add this to the spin out, the reverse split, the uplist, etc. Gerald has promised just about every holy grail in the book (Minus the R/S) and still nothing has come from it.

Even if they split it up to the NASDAQ, they won't be able to keep it there without significant Lympro revenues.

And If they spin out diagnostics, the R&D entity will have no revenues to speak of and become a huge dilution vehicle.

After today, there's a lot more riding on Lympro revenues than there was previously.